Article Text

Download PDFPDF
News and updates from
  1. Andrew Wilcock1 and
  2. Sarah Charlesworth2
  1. 1Department of Palliative Medicine, University of Nottingham, Nottingham, UK
  2. 2Hayward House Study Centre, Nottingham University Hospitals NHS Trust,, Nottingham, UK
  1. Correspondence to Sarah Charlesworth, Hayward House Study Centre, Nottingham University Hospitals NHS Trust,, Nottingham NG5 1PB, UK; s.charlesworth{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The website has provided essential independent information about drugs used in palliative and hospice care for over a decade, and has over 30 000 members from 169 Countries. It contains the on-line Palliative Care Formulary (PCF) and provides free access to a Bulletin board to stimulate questions and share experiences, a Document library containing 475 items of useful information and a Syringe Driver Survey Database containing details of over 2350 different drug combinations. Territory-specific book versions (the UK Palliative Care Formulary fifth edition, Hospice and Palliative Care Formulary USA second edition and Palliative Care Formulary Canadian edition) a PDF version of the PCF and subscription to the continually updated on-line PCF can also be purchased via the website. This feature provides a selection of items that have featured in the News and Latest additions sections in recent months; for additional information, please register for free on the website.

Safety updates

Naloxone—Patient Safety Alert

National Health Service (NHS) England has produced a second Patient Safety Alert (NHS/PSA/Re/2015/009) regarding inappropriate doses of naloxone in patients on long-term opioid treatment. The stage two Resource Alert points to the resources that have been developed in response to the stage one Alert issued in November 2014 (NHS/PSA/W/2014/016R). The new alert is intended to support all providers of NHS funded care to ensure local protocols and training related to use of naloxone reflect best practice.

Note: The information from the original stage one alert is reflected in the PCF Opioid antagonist monograph. In addition, there is information on even lower initial doses (naloxone 20 µg intravenous) being used for the reversal of respiratory depression caused by the medicinal use of opioids as recommended by …

View Full Text


  • Twitter Follow at @palliativedrugs

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; internally peer reviewed.